title: Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim.
authors.forename: David
authors.initials: D
authors.lastname: Groheux
authors.forename: Sylvie
authors.initials: S
authors.lastname: Giacchetti
authors.forename: Marc
authors.initials: M
authors.lastname: Espié
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
authors.forename: Jean-luc
authors.initials: JL
authors.lastname: Moretti
authors.forename: Elif
authors.initials: E
authors.lastname: Hindié
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D002986:Clinical Trials as Topic; D019788:Fluorodeoxyglucose F18; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D020360:Neoadjuvant Therapy; D049268:Positron-Emission Tomography / Q000379:methods* / Q000592:standards; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D012015:Reference Standards; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000379:methods* / Q000592:standards; D016896:Treatment Outcome
chemical_list: D019788:Fluorodeoxyglucose F18; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C508053:ERBB2 protein, human